Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12

NCT00944034 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT00944034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00944034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12
Lead sponsor
Novartis Vaccines
Phase
Phase 2/3
Overall status
Completed
Start date
July 31, 2009
Completion date
January 31, 2012
Enrollment
1,588 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease, meningococcal meningitis